Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBZ27L)

• Drug Name: Favipiravir Drug Info
• Synonyms: AIDS121660; Favipiravir (JAN/INN); 3-bromo-5-hydroxy-4-methyl-2,6-dinitro-benzoic Acid; T705

Indication

Disease Entry	ICD 11	Status	REF
Influenza virus infection	1E30-1E32	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[2]

• Cross-matching ID:
  PubChem CID: 492405
  ChEBI ID: CHEBI:134722
  CAS Number: CAS 259793-96-9
  TTD Drug ID: DMBZ27L

Molecule-Related Drug Atlas

Drug(s) Targeting Mycobacterium RNA polymerase (MycB RNAP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rifamycin	DMEH3O7	Diarrhea	ME05.1	Approved	[5]
TAS-106	DML97KB	Head and neck cancer	2D42	Phase 2	[6]
JTK-003	DMB0V5Y	Hepatitis C virus infection	1E51.1	Discontinued in Phase 2	[7]
R-1479	DM9C6LN	Hepatitis C virus infection	1E51.1	Discontinued in Phase 1	[8]
XTL-2125	DM3Y6M7	Hepatitis C virus infection	1E51.1	Discontinued in Phase 1	[9]

Drug(s) Targeting COVID-19 RNA-directed RNA polymerase (RdRp)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Remdesivir	DMBFZ6L	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved	[10]
Remdesivir	DMBFZ6L	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved	[11]
Penciclovir	DMOUMDV	Herpes simplex labialis	1F00.01	Approved	[10]
Anidulafungin	DM8QM5U	Aspergillosis	1F20	Approved	[12]
Galidesivir	DMG9C4I	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1 Trial	[13]
Suramin	DMTOUY9	African trypanosomiasis	1F51	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mycobacterium RNA polymerase (MycB RNAP)	TT79JGK	RPOA_MYCTU; RPOB_MYCTU; RPOC_MYCTU; RPOZ_MYCTU	Modulator	[3]
COVID-19 RNA-directed RNA polymerase (RdRp)	TTV1095	R1AB_SARS2 (4393-5324)	Inhibitor	[4]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] ClinicalTrials.gov (NCT04336904) Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
• [3] Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res.2013 Nov;100(2):446-54.
• [4] Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. Posted April 15, 2020.
• [5] Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4832-E4840.
• [6] Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.Invest New Drugs.2012 Feb;30(1):316-26.
• [7] Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care. Viruses. 2010 April; 2(4): 826-866.
• [8] The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cel... J Biol Chem. 2006 Feb 17;281(7):3793-9.
• [9] DOI: 10.1111/j.1365-2036.2009.03927.x
• [10] Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [12] Suramin, Penciclovir and Anidulafungin bind nsp12, which governs the RNA-dependent-RNA polymerase activity of SARS-CoV-2, with higher interaction energy than Remdesivir, indicating potential in the treatment of Covid-19 infection. April.21.2020. Doi: 10.31219/osf.io/urxwh
• [13] BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19